Role of Interleukin-6 as a Predictor in Assessing Severity of COVID-19 Patients: A Hospital Based Cross-Sectional Study

The investigation is centered on evaluating the impact of interleukin-6 (IL-6) on determining the seriousness of COVID-19 among individuals in Bangladesh, a nation grappling with substantial challenges due to the outbreak. Given the absence of specific therapies for COVID-19, grasping biomarkers such as IL-6 becomes pivotal for prognosis and treatment. The primary objective of the study is to outline the socio-demographic attributes of COVID-19 patients, ascertain IL-6 concentrations, evaluate the disease's severity based on IL-6 levels, and recognize correlated comorbidities. Through the analysis of 90 patients in specialized COVID-19 facilities in Dhaka, information regarding IL-6 levels, socio-demographics, clinical characteristics, and comorbidities was gathered. The conclusions of the research contribute to enhancing the comprehension of the connection between IL-6 and COVID-19 severity, potentially facilitating early prognosis and intervention strategies. Such perceptions are imperative for healthcare practitioners to implement practices grounded on evidence and alleviate the repercussions of the outbreak. This particular Hospital-Based Cross-sectional Study delves into the function of Interleukin-6 (IL-6) as an indicator for evaluating the severity of COVID-19 patients. A total of 90 participants from COVID dedicated hospitals were examined, with demographic characteristics scrutinized alongside COVID symptoms, oxygen saturation levels, and IL-6 concentrations. The results indicate a notable correlation between IL-6 levels and COVID severity, with heightened IL-6 levels corresponding to severe instances. Suggestions encompass the utilization of IL-6 and other inflammatory markers for predicting severity and advocating for further extensive studies to guide policymaking. Despite drawbacks such as limitations in sample size, IL-6 emerges as a promising indicator for early identification of COVID-19 severity.